In the context of ischemic stroke, although LRRC8A inhibition demonstrates neuroprotective potential, uncertainty remains regarding the optimal therapeutic window, the complex interplay between multiple LRRC8A-mediated signaling cascades, and the specificity of DCPIB as an LRRC8A inhibitor utilized in experimental paradigms. This evidence concerns the gene LRRC8A and ischemic stroke.